Top

Published in:

19-06-2023 | Systemic Sclerosis | Review Article

Serum markers in systemic sclerosis with cardiac involvement

Author: Neslihan Gokcen

Published in: Clinical Rheumatology | Issue 10/2023

Abstract

Cardiac involvement in systemic sclerosis is a common clinical entity that may range from subclinical to life-threatening complications. The classification of cardiac involvement may be expressed as either primary or secondary involvement. Primary systemic sclerosis heart involvement (SSc-pHI) refers to cardiac pathologies primarily ascribed to systemic sclerosis rather than concomitant conditions like ischemic heart disease and pulmonary hypertension. The timely recognition of cardiac involvement holds significant clinical relevance. Therefore, numerous screening or diagnostic tools have been evaluated to forecast the likelihood of cardiac involvement, particularly in the absence of clinically evident cardiac symptoms. Of these modalities, serum biomarkers are often preferred due to their expeditiousness and non-invasive nature. Hence, the crucial goal of this narrative review is to review serum biomarkers that can be a valuable or promising tool in diagnosing cardiac involvement, especially SSc-pHI, in the early stages or predicting disease prognosis.

Volkmann ER, Andréasson K, Smith V (2023) Systemic sclerosis. Lancet 401(10373):304–318. https://doi.org/10.1016/S0140-6736(22)01692-0CrossRefPubMed

Deswal A, Follansbee WP (1996) Cardiac involvement in scleroderma. Rheum Dis Clin North Am 22(4):841–860. https://doi.org/10.1016/s0889-857x(05)70304-5CrossRefPubMed

Moysidou GS, Dara A, Arvanitaki A, Skalkou A, Pagkopoulou E, Daoussis D et al (2023) Understanding and managing cardiac involvement in systemic sclerosis. Expert Rev Clin Immunol 19(3):293–304. https://doi.org/10.1080/1744666X.2023.2171988CrossRefPubMed

Caetano J, Batista F, Amaral MC, Oliveira S, Alves JD (2022) Acute hospitalization in a cohort of patients with systemic sclerosis: a 10-year retrospective cohort study. Rheumatol Int 42(8):1393–1402. https://doi.org/10.1007/s00296-021-04983-4CrossRefPubMed

Agoston Coldea L, Zlibut A, Revnic R, Florea M, Muntean L (2021) Current advances in cardiac magnetic resonance imaging in systemic sclerosis. Eur Rev Med Pharmacol Sci 25(10):3718–3736. https://doi.org/10.26355/eurrev_202105_25940CrossRefPubMed

Bruni C, Ross L (2021) Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. Best Pract Res Clin Rheumatol 35(3):101668. https://doi.org/10.1016/j.berh.2021.101668CrossRefPubMed

Bruni C, Buch MH, Furst DE, De Luca G, Djokovic A, Dumitru RB et al (2022) Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord 7(1):24–32. https://doi.org/10.1177/23971983211053246CrossRefPubMed

EUSTAR co-authors, Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P et al (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69(1):218–221. https://doi.org/10.1136/ard.2008.103382CrossRef

Nie LY, Wang XD, Zhang T, Xue J (2019) Cardiac complications in systemic sclerosis: early diagnosis and treatment. Chin Med J (Engl) 132(23):2865–2871. https://doi.org/10.1097/CM9.0000000000000535CrossRefPubMed

10.

Afifi N, Khalifa MMM, Al Anany AAMMM, Hassan HGEMA (2022) Cardiac calcium score in systemic sclerosis. Clin Rheumatol 41(1):105–114. https://doi.org/10.1007/s10067-021-05887-1CrossRefPubMed

11.

Ferlito A, Campochiaro C, Tomelleri A, Dagna L, De Luca G (2022) Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. J Scleroderma Relat Disord 7(3):179–188. https://doi.org/10.1177/23971983221083772CrossRefPubMedPubMedCentral

12.

De Luca G, Cavalli G, Campochiaro C, Bruni C, Tomelleri A, Dagna L, Matucci-Cerinic M (2021) Interleukin-1 and systemic sclerosis: getting to the heart of cardiac involvement. Front Immunol 12:653950. https://doi.org/10.3389/fimmu.2021.653950CrossRefPubMedPubMedCentral

13.

Caforio ALP, De Luca G, Baritussio A, Seguso M, Gallo N, Bison E et al (2021) Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: frequency, clinical and prognostic correlates. Diagnostics (Basel) 11(11):2165. https://doi.org/10.3390/diagnostics11112165CrossRefPubMed

14.

RESCLE Investigators, Systemic Autoimmune Diseases Study Group (GEAS), González García A, Fabregate M, Manzano L, Guillén Del Castillo A, Rubio Rivas M, Argibay A et al (2022) Left ventricular diastolic dysfunction in systemic sclerosis: clinical, immunological and survival differences in the Spanish RESCLE registry. Semin Arthritis Rheum 55:152033. https://doi.org/10.1016/j.semarthrit.2022.152033CrossRef

15.

Hui M, Zhou J, Zhang L, Duan X, Li M, Wang Q et al (2021) Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. Clin Rheumatol 40(11):4589–4596. https://doi.org/10.1007/s10067-021-05804-6 Epub 2021 Jun 17CrossRefPubMed

16.

Varga J, Lee DC (2019) Getting to the heart of the matter: detecting and managing cardiac complications in systemic sclerosis. Ann Rheum Dis 78(11):1452–1453. https://doi.org/10.1136/annrheumdis-2019-216115CrossRefPubMed

17.

Hinze AM, Perin J, Woods A, Hummers LK, Wigley FM, Mukherjee M, Shah AA (2022) Diastolic dysfunction in systemic sclerosis: risk factors and impact on mortality. Arthritis Rheumatol 74(5):849–859. https://doi.org/10.1002/art.42054CrossRefPubMedPubMedCentral

18.

EUSTAR group, Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76(11):1897–1905. https://doi.org/10.1136/annrheumdis-2017-211448CrossRef

19.

Feher A, Miller EJ, Peters DC, Mojibian HR, Sinusas AJ, Hinchcliff M, Baldassarre LA (2023) Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis. Rheumatol Int 43(5):849–858. https://doi.org/10.1007/s00296-023-05294-6CrossRefPubMed

20.

Gawałko M, Balsam P, Lodziński P, Grabowski M, Krzowski B, Opolski G, Kosiuk J (2020) Cardiac Arrhythmias in Autoimmune Diseases. Circ J 84(5):685–694. https://doi.org/10.1253/circj.CJ-19-0705CrossRefPubMed

21.

Hu S, Hou Y, Wang Q, Li M, Xu D, Zeng X (2018) Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. Arthritis Res Ther 20(1):235. https://doi.org/10.1186/s13075-018-1735-4CrossRefPubMedPubMedCentral

22.

Hosoya H, Derk CT (2018) Clinically symptomatic pericardial effusions in hospitalized systemic sclerosis patients: demographics and management. Biomed Res Int 2018:6812082. https://doi.org/10.1155/2018/6812082CrossRefPubMedPubMedCentral

23.

Colaci M, Schinocca C, Bosco YD, Ronsivalle G, Guggino G, de Andres I et al (2022) Heart valve abnormalities in systemic sclerosis patients: a multicenter cohort study and review of the literature. J Clin Rheumatol 28(1):e95–e101. https://doi.org/10.1097/RHU.0000000000001638CrossRefPubMed

24.

Kurmann RD, El-Am EA, Radwan YA, Sandhu AS, Crowson CS, Matteson EL et al (2021) Increased risk of valvular heart disease in systemic sclerosis: an underrecognized cardiac complication. J Rheumatol 48(7):1047–1052. https://doi.org/10.3899/jrheum.201005CrossRefPubMedPubMedCentral

25.

Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega JC et al (2019) Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther 21(1):86. https://doi.org/10.1186/s13075-019-1867-1CrossRefPubMedPubMedCentral

26.

Li X, Qian YQ, Liu N, Mu R, Zuo Y, Wang GC, Jia Y, Li ZG (2018) Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study. Clin Rheumatol 37(11):3051–3056. https://doi.org/10.1007/s10067-018-4291-zCrossRefPubMed

27.

Abignano G, Del Galdo F (2020) Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. Eur J Rheumatol 7(Suppl 3):S193–S202. https://doi.org/10.5152/eurjrheum.2020.19065CrossRefPubMedPubMedCentral

28.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

29.

Romaniello A, Rubattu S, Gigante A, Simonelli F, Grimaldi MC, D'Angelo A et al (2019) Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. J Cardiovasc Med (Hagerstown) 20(11):771–779. https://doi.org/10.2459/JCM.0000000000000852CrossRefPubMed

30.

Ross L, Moxey J, Nikpour M (2021) Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. Semin Arthritis Rheum 51(1):299–309. https://doi.org/10.1016/j.semarthrit.2020.10.016CrossRefPubMed

31.

Dumitru RB, Bissell LA, Erhayiem B, Fent G, Kidambi A, Swoboda P et al (2021) Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. Rheumatology (Oxford) 60(6):2934–2945. https://doi.org/10.1093/rheumatology/keaa742CrossRefPubMed

32.

Barsotti S, Stagnaro C, d'Ascanio A, Parma A, Emdin M, Conti U et al (2017) High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. J Scleroderma Relat Disord 2(3):183–187CrossRef

33.

Bosello S, De Luca G, Berardi G, Canestrari G, de Waure C, Gabrielli FA et al (2019) Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: a prospective study. Eur J Intern Med 60:46–53. https://doi.org/10.1016/j.ejim.2018.10.013CrossRefPubMed

34.

Jha M, Wang M, Steele R, Baron M, Fritzler MJ, Canadian Scleroderma Research Group, Hudson M (2022) NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. J Scleroderma Relat Disord 7(1):62–70. https://doi.org/10.1177/23971983211040608CrossRefPubMed

35.

Paik JJ, Choi DY, Mukherjee M, Hsu S, Wigley F, Shah AA, Hummers LK (2022) Troponin elevation independently associates with mortality in systemic sclerosis. Clin Exp Rheumatol 40(10):1933–1940. https://doi.org/10.55563/clinexprheumatol/fytfmyCrossRefPubMedPubMedCentral

36.

Nordin A, Svenungsson E, Björnådal L, Elvin K, Larsson A, Jensen-Urstad K (2017) Troponin I and echocardiography in patients with systemic sclerosis and matched population controls. Scand J Rheumatol 46(3):226–235. https://doi.org/10.1080/03009742.2016.1192217CrossRefPubMed

37.

Bissell LA, Dumitru RB, Erhayiem B, Abignano G, Fent G, Kidambi A et al (2019) Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP. Rheumatology (Oxford) 58(7):1221–1226. https://doi.org/10.1093/rheumatology/key430CrossRefPubMed

38.

Sugiyama K, Kobayashi H, Kobayashi Y, Yokoe I, Takei M, Kitamura N (2019) Association of cardiac magnetic resonance-detected myocardial abnormalities with disease characteristics and brain natriuretic peptide levels in systemic sclerosis without cardiac symptoms. Int J Rheum Dis 22(6):1016–1022. https://doi.org/10.1111/1756-185X.13540CrossRefPubMed

39.

Dumitru RB, Bissell LA, Erhayiem B, Kidambi A, Dumitru AH, Fent G et al (2021) Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. RMD Open 7(3):e001689. https://doi.org/10.1136/rmdopen-2021-001689CrossRefPubMedPubMedCentral

40.

Tipparot T, Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R, Pussadhamma B, Chaosuwannakit N (2019) Clinical and laboratory predictions of myocardial inflammation as detected by cardiac magnetic resonance imaging in patients with systemic sclerosis: A pilot study. Int J Rheum Dis 22(12):2125–2133. https://doi.org/10.1111/1756-185X.13727CrossRefPubMed

41.

Hromadka M, Baxa J, Seidlerova J, Miklik R, Rajdl D, Sudova V et al (2021) Myocardial involvement detected using cardiac magnetic resonance imaging in patients with systemic sclerosis: A Prospective observational study. J Clin Med 10(22):5364. https://doi.org/10.3390/jcm10225364CrossRefPubMedPubMedCentral

42.

De Luca G, Campochiaro C, De Santis M, Sartorelli S, Peretto G, Sala S et al (2020) Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology (Oxford) 59(9):2523–2533. https://doi.org/10.1093/rheumatology/kez658CrossRefPubMed

43.

Hromadka M, Seidlerova J, Suchy D, Rajdl D, Lhotsky J, Ludvik J et al (2017) Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients- relationship with biochemical and echocardiography parameters. Int J Cardiol 249:448–453. https://doi.org/10.1016/j.ijcard.2017.08.072CrossRefPubMed

44.

Vertes V, Porpaczy A, Nogradi A, Tokes-Fuzesi M, Hajdu M, Czirjak L et al (2022) Galectin-3 and sST2: associations to the echocardiographic markers of the myocardial mechanics in systemic sclerosis - a pilot study. Cardiovasc Ultrasound 20(1):1. https://doi.org/10.1186/s12947-022-00272-7CrossRefPubMedPubMedCentral

45.

Tennoe AH, Murbræch K, Didriksen H, Ueland T, Palchevskiy V, Weigt SS et al (2022) Serum markers of cardiac complications in a systemic sclerosis cohort. Sci Rep 12(1):4661. https://doi.org/10.1038/s41598-022-08815-8CrossRefPubMedPubMedCentral

46.

Iannazzo F, Pellicano C, Colalillo A, Ramaccini C, Romaniello A, Gigante A, Rosato E (2022) Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement. Clin Exp Med. https://doi.org/10.1007/s10238-022-00864-7

47.

El-Adili F, Lui JK, Najem M, Farina G, Trojanowska M, Sam F, Bujor AM (2023) Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. Arthritis Res Ther 25(1):11. https://doi.org/10.1186/s13075-022-02943-2CrossRefPubMedPubMedCentral

48.

Leclair V, D'Aoust J, Gyger G, Landon-Cardinal O, Meyer A, O'Ferrall E et al (2022) Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology (Oxford) 61(3):1148–1157. https://doi.org/10.1093/rheumatology/keab492CrossRefPubMed

49.

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747–1755. https://doi.org/10.1136/annrheumdis-2013-204424CrossRefPubMed

50.

Nihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett-Smith EC, Fonseca C et al (2020) Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol 72(3):465–476. https://doi.org/10.1002/art.41153CrossRefPubMed

51.

Tieu A, Chaigne B, Dunogue B, Dion J, Regent A, Casadevall M et al (2022) Autoantibodies versus skin fibrosis extent in systemic sclerosis: a case-control study of inverted phenotypes. Diagnostics (Basel) 12(5):1067. https://doi.org/10.3390/diagnostics12051067CrossRefPubMed

52.

Keppeke GD, Satoh M, Kayser C, Matos P, Hasegawa T, Tanaka S et al (2022) A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front Immunol 13:1011110. https://doi.org/10.3389/fimmu.2022.1011110CrossRefPubMedPubMedCentral

53.

Psarras A, Soulaidopoulos S, Garyfallos A, Kitas G, Dimitroulas T (2017) A critical view on cardiovascular risk in systemic sclerosis. Rheumatol Int 37(1):85–95. https://doi.org/10.1007/s00296-016-3530-3CrossRefPubMed

Title: Serum markers in systemic sclerosis with cardiac involvement
Author: Neslihan Gokcen
Publication date: 19-06-2023
Publisher: Springer International Publishing
Keywords: Systemic Sclerosis
Myocarditis
Pulmonary Hypertension
Pulmonary Hypertension
Biomarkers
Pulmonary Hypertension
Pulmonary Hypertension
Published in: Clinical Rheumatology / Issue 10/2023
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06663-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2023

The phenotype and genotype of Chinese adult patients with NLRP3-associated autoinflammatory disease

Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease

Occurrence and localization of FOXP3 + cells in kidney biopsies in lupus nephritis and ANCA-associated vasculitis

Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study

Characterization of virus-mediated autoimmunity and the consequences for pathological process in patients with systemic lupus erythematosus

Autonomic dysfunction and cardiovascular risk in psoriatic arthritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials